Countdown to Humana (HUM) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

06.02.25 15:15 Uhr

Werte in diesem Artikel
Aktien

278,90 EUR -3,40 EUR -1,20%

Indizes

6.061,5 PKT 23,6 PKT 0,39%

Analysts on Wall Street project that Humana (HUM) will announce quarterly loss of $2.26 per share in its forthcoming report, representing a decline of 1954.6% year over year. Revenues are projected to reach $28.82 billion, increasing 12% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.7% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.Given this perspective, it's time to examine the average forecasts of specific Humana metrics that are routinely monitored and predicted by Wall Street analysts.Analysts expect 'Revenues- Premiums' to come in at $27.37 billion. The estimate indicates a change of +8.9% from the prior-year quarter.According to the collective judgment of analysts, 'Revenues- Investment income (loss)' should come in at $317.22 million. The estimate points to a change of +7.9% from the year-ago quarter.The consensus estimate for 'Revenues- Services' stands at $1.07 billion. The estimate suggests a change of +3.2% year over year.Analysts forecast 'Revenue- CenterWell' to reach $4.89 billion. The estimate indicates a year-over-year change of +3.8%.The consensus among analysts is that 'Benefits Expense Ratio - Consolidated' will reach 91.3%. Compared to the current estimate, the company reported 90.7% in the same quarter of the previous year.It is projected by analysts that the 'Medical Membership - Group Medicare Advantage' will reach 544.72 thousand. The estimate is in contrast to the year-ago figure of 509.6 thousand.Analysts' assessment points toward 'Medical Membership - Medicare stand-alone PDP' reaching 2.26 million. Compared to the present estimate, the company reported 2.85 million in the same quarter last year.Analysts predict that the 'Medical Membership - Individual Medicare Advantage' will reach 5.67 million. The estimate is in contrast to the year-ago figure of 5.41 million.The average prediction of analysts places 'Medical Membership - Total Medicare' at 8.47 million. The estimate is in contrast to the year-ago figure of 8.77 million.The collective assessment of analysts points to an estimated 'Medical Membership - Medicare Supplement' of 353.43 thousand. The estimate is in contrast to the year-ago figure of 307.2 thousand.Based on the collective assessment of analysts, 'Medical Membership - Military services' should arrive at 5.98 million. Compared to the current estimate, the company reported 5.96 million in the same quarter of the previous year.The combined assessment of analysts suggests that 'Specialty membership - Total' will likely reach 4.31 million. The estimate is in contrast to the year-ago figure of 4.87 million.View all Key Company Metrics for Humana here>>>Shares of Humana have experienced a change of +8.4% in the past month compared to the +2.1% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), HUM is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humana Inc. (HUM): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Humana

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Humana

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Humana Inc.

Wer­bung

Analysen zu Humana Inc.

DatumRatingAnalyst
12.08.2019Humana OverweightCantor Fitzgerald
13.09.2018Humana OverweightBarclays Capital
09.11.2017Humana Sector PerformRBC Capital Markets
20.10.2017Humana OutperformBMO Capital Markets
05.04.2017Humana HoldDeutsche Bank AG
DatumRatingAnalyst
12.08.2019Humana OverweightCantor Fitzgerald
13.09.2018Humana OverweightBarclays Capital
20.10.2017Humana OutperformBMO Capital Markets
24.01.2017Humana HoldStifel, Nicolaus & Co., Inc.
05.05.2016Humana BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
09.11.2017Humana Sector PerformRBC Capital Markets
05.04.2017Humana HoldDeutsche Bank AG
07.12.2016Humana HoldCantor Fitzgerald
13.10.2016Humana Sector PerformRBC Capital Markets
22.07.2016Humana Mkt PerformFBR Capital
DatumRatingAnalyst
14.03.2008Humana neues KurszielLehman Brothers Inc.
03.02.2006Update Humana Inc.: UnderperformCredit Suisse First Boston
26.01.2006Update Humana Inc.: ReduceUBS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Humana Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"